Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PPM1B | O75688 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30289815 | 1.00 | HPGD (0.46) | HPGDNPC1TP53CYP1A2CYP2C9 | |
| SCHEMBL8627456 | 0.94 | HPGD (0.50) | HPGDNPC1TP53CYP1A2CYP2C9 | |
| SCHEMBL1813924 | 0.94 | HPGD (0.50) | HPGDNPC1TP53CYP1A2CYP2C9 | |
| SCHEMBL8626242 | 0.94 | HPGD (0.50) | HPGDNPC1TP53CYP1A2CYP2C9 | |
| SCHEMBL19565576 | 0.88 | — | — | |
| SCHEMBL19565577 | 0.88 | — | — | |
| SCHEMBL4914627 | 0.88 | — | — | |
| SCHEMBL16327961 | 0.81 | CYP1A2 (0.38) | HPGDNPC1TP53CYP1A2CYP2C9 | |
| SCHEMBL30232114 | 0.80 | HPGD (0.37) | HPGDNPC1TP53CYP1A2CYP2C9 | |
| SCHEMBL17361182 | 0.80 | ALDH1A1 (0.52) | HPGDNPC1TP53CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116322696-A | Heterocyclic compounds as receptor 2-triggering agonists expressed on myeloid cells and methods of use | 安进公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115896065-A | Stereoselective carboxylesterase, encoding gene, vector and application thereof | 江南大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-112898309-A | Tricyclic compounds as immunomodulators | 正大天晴药业集团股份有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-108884103-B | Tricyclic compounds as immunomodulators | 正大天晴药业集团股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| CN-110121497-A | Amidine catalyst for curable compositions | SIKA技术股份公司 | 2019-08-13 | — | — | CN | disclosed |
| US-7465817-B2 | Inositolized phospholipids | CHARITE-UNIVERSITATS MEDIZIN BERLIN (DE) | 2008-12-16 | — | — | US | disclosed |
| US-20080227763-A1 | Administering hormone replacement therapy by applying a gel of Nomegestrol or Nomegestrol acetate to the skin; restoring genital bleeding in menopausal women | LABORATOIRE THERAMEX | 2008-09-18 | — | — | US | disclosed |
| EP-1562609-B1 | INOSITOLIZED PHOSPHOLIPIDS | CHARITE UNIVERSITAETSMEDIZIN (DE) | 2006-10-25 | — | — | EP | disclosed |
| US-20060105996-A1 | Inositolized phospholipids | CHARITE-UNIVERSITATS MEDIZIN BERLIN (DE) | 2006-05-18 | — | — | US | disclosed |
| EP-1615899-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACIDS AS PPAR MODULATORS | PFIZER INC. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092145-A1 | ALPHA SUBSTITUTED CARBOXYLIC ACID AS PPAR MODULATORS | PFIZER INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| CN-1161102-C | Systemic topical hormone compositions | ̩��÷˹ʵ���� | 2004-08-11 | — | — | CN | disclosed |
| WO-2004045623-A1 | INOSITOLIZED PHOSPHOLIPIDS | CHARITÉ-UNIVERSITÄTS MEDIZIN BERLIN (DE) | 2004-06-03 | — | — | WO | disclosed |
| EP-1421941-A1 | Phospholipid derivatives having a polyhydroxylated aliphatic carbocycle | Reutter, Werner, Prof. Dr. (DE) | 2004-05-26 | — | — | EP | disclosed |
| CN-1301146-A | Topical hormonal composition with systemic effect | THERAMEX (MC) | 2001-06-27 | — | — | CN | disclosed |
| US-6087509-A | DERIVATIVES OF TRIFLUOROBENZONITRILES | HOECHST MARION ROUSSEL (FR) | 2000-07-11 | — | — | US | disclosed |
| US-5750553-A | ANTIANDROGENIC AGENTS | ROUSSEL UCLAF (FR) | 1998-05-12 | — | — | US | disclosed |
| US-5399590-A | Treatment of skin tumors, rheumatic diseases | GASTAUD JEAN M (FR) | 1995-03-21 | — | — | US | disclosed |
| CN-1024013-C | Cationic complexes of technetium-99 m | AMERSHAM INTERNATION PLC (GB) | 1994-03-16 | — | — | CN | disclosed |
| CN-1042543-A | The cationic complex of technetium-99m | AMERSHAM INTERNATION PLC (GB) | 1990-05-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105996-A1 | Inositolized phospholipids | PHOSPHO1, SGMS1, CDIPT | HPGD 1416/4885NPC1 196/4885TP53 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.